stockrow
Friday 6 November 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
Bolt Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, roughly unchanged from fiscal 2024.
- Revenue
- −99.7%
- EPS
- −2.47%
- Free cash flow
- +38.9%
- Total debt
- −14.3%
Quarter to June 2026, against a year earlier
6.52
0.14
+2.19%
Follow BOLT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | 1 | 6 | 8 | 8 | 8 | 5 | +81.5% | 0 | 0 | 0 | (96.1%) | |
| Gross margin, % | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | (12) | (30) | (61) | (99) | (88) | (69) | (63) | (33) | (29) | +16.3% | ||||||
| EBT margin, % | — | — | 0.00 | (14,180.00) | (26,289.18) | (7,824.68) | (1,537.76) | (878.58) | (820.78) | (433.74) | (611.47) | (433.7) pt | ||||||
| Net income | — | 0 | (12) | (30) | (61) | (99) | (88) | (69) | (63) | (33) | (29) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 2.16 | 2.20 | 0.76 | 3.07 | 4.17 | 4.03 | 4.12 | 2.78 | n/m | |||||
| Earnings | — | — | (0.33) | (305.94) | (577.80) | (59.40) | (47.20) | (36.60) | (33.00) | (17.85) | (16.44) | +76.8% | ||||||
| Cash flow | — | — | (0.28) | (264.22) | (450.12) | (34.38) | (40.96) | (36.77) | (32.11) | (21.31) | (18.60) | +85.6% | ||||||
| Capex | — | — | 0.00 | (5.10) | (31.04) | (1.41) | (1.05) | (0.11) | 0.06 | 0.48 | 0.37 | n/m | ||||||
| Free cash flow | — | — | (0.28) | (269.32) | (481.16) | (35.79) | (42.00) | (36.88) | (32.05) | (20.83) | (18.23) | +85.0% | ||||||
| Book value | — | — | 0.35 | 317.54 | 3.32 | 150.68 | 91.82 | 59.63 | 29.96 | 14.17 | 7.47 | +69.4% | ||||||
| Shares, m | — | — | 35 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | (34.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 0.00 | 109.10 | 8.93 | 5.57 | 2.66 | 1.33 | 2.35 | 18.2 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 0.65 | 0.30 | 0.39 | 0.36 | 0.39 | 0.87 | 0.3 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.00 | (1.14) | (17.02) | (5.19) | (0.61) | 0.35 | 2.51 | (3.4) | ||||||
| EV/FCF | — | — | — | (1.09) | (1.09) | 0.03 | 1.24 | 0.59 | 0.08 | (0.07) | (0.38) | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (10) | (26) | (47) | (57) | (77) | (70) | (61) | (40) | (31) | +22.1% | |||||
| Capex | — | — | 0 | (1) | (3) | (2) | (2) | 0 | 0 | 1 | 1 | n/m | ||||||
| Free cash flow | — | — | (10) | (27) | (51) | (59) | (78) | (70) | (61) | (39) | (31) | +21.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 11 | 27 | 14 | 168 | 150 | 85 | 35 | 22 | 13 | +9.8% | |||||
| Net debt | — | — | (14) | (28) | (13) | (164) | (149) | (85) | (25) | (8) | 1 | (8.0%) | ||||||
| Shareholders’ equity | — | — | 12 | 32 | 0 | 250 | 172 | 113 | 57 | 27 | 13 | +11.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (145.09) | (94.65) | (127.86) | (55.66) | (32.90) | (35.71) | (48.66) | (42.69) | (49.62) | +102.4 pt | |||||
| ROIC | — | — | 0.00 | (493.51) | 0.00 | (67.63) | (247.18) | (170.15) | (142.45) | (119.22) | (143.75) | (119.2) pt | ||||||
| ROE | — | — | 37.51 | 98.68 | 80.54 | (135.83) | (41.79) | (48.69) | (74.28) | (79.75) | (111.65) | (117.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 65 | 91 | 94 | 100 | 52 | 23 | — | (18.8%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.01 | 0.06 | 0.08 | 0.15 | 0.33 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Bolt Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $14.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $12.3M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | |
| DARE Dare Bioscience, Inc. | $12.3M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| GUTS Fractyl Health, Inc. | $11.9M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HIND Vyome Holdings, Inc. | $11.4M | — (loss-making) | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $12.1M | — | — | −45.93% | — | −107.30% | 51.14% | (37.93%) |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
9.40%
Sofinnova Venture Partners X, L.P.
7.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement